TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03135262

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab will be administered by IV infusion at a dose of 375 milligrams per square meter (mg/m\^2) on Day 1 of Cycles 1-6 during induction treatment and on Day 1 of every other month during consolidation treatment.
Study: NCT00641706

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vorinostat
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vorinostat
Description: Given orally
Study: NCT03533764

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ASMA
Description: ASMA, grounded in social cognitive theory and utilizing motivational interviewing techniques, guides adolescents in their transition to being consumers and teaching them to navigate the health system, including overcoming challenges to health care access. Briefly, it consists of three complementary components: (1) an 8- week intervention for students; (2) caregiver education; and (3) education for students' medical providers.
Study: NCT06074367

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin C 500 MG Oral Capsule(High dose 2g daily)
Description: A sixty CABG patients commenced on maximum tolerated dose of b-blocker, statins \& vitamin C 500 mg (2 g-daily in 4 divided doses) started one day before operation till the end of hospital stay or development of post operative atrial fibrillation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin C 500 MG Oral Capsule(Low-dose 1g daily)
Description: A sixty CABG patients commenced on maximum tolerated dose of b-blocker, statins, vitamin C 500 mg (1 g-daily in 2 divided doses) and also received 2 capsules containing starch to be completely equivalent in frequency to the other groups. the intervention started one day before operation till the end of hospital stay or development of post operative atrial fibrillation.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo capsules
Description: A sixty CABG Patients commenced on maximum tolerated dose of b-blocker, statins and placebo capsules containing starch mimic vitamin C capsules was taken every 6 hrs. The placebo capsules were prepared in the same shape and size as the original ones manufactured by the same pharmaceutical company. the intervention started one day before operation till the end of hospital stay or development of post operative atrial fibrillation.
Study: NCT02549937

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: surufatinib
Description: orally once daily (QD) in patients with advanced solid tumor.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: surufatinib
Description: orally once daily (QD) in patients with advanced solid tumor.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: surufatinib
Description: orally once daily (QD) in patients with advanced solid tumor.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: surufatinib
Description: orally once daily (QD) in patients with advanced solid tumor.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: surufatinib
Description: orally once daily (QD) in patients with advanced solid tumor.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: surufatinib
Description: orally once daily (QD) in patients with advanced solid tumor.
Study: NCT01421004

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TKI258

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TKI258
Study: NCT00662012

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Stibogluconate (SSG)
Description: 100 mg/ml/vial. Treatment for laboratory-confirmed leishmaniasis with SSG 20mg/kg/d intravenously (IV) for 10 days or 20 days for less responsive; visceral leishmaniasis will be treated with SSG 20mg/kg/d IV for 28 days as a second line of therapy for those failing or intolerant of Ambisome; and mucosal leishmaniasis will be treated with SSG 20mg/kg/d IV for 28 days.
Study: NCT03955744

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 3D translabial ultrasound
Description: All patients will undergo 3D translabial ultrasound with vaginal manometry
Study: NCT03992001

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood component A
Description: PRBCs obtained from whole blood after separation of plasma, buffy coat, and RBCs and successive leukoreduction of RBCs

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood component A
Description: PRBCs obtained from whole blood after separation of plasma, buffy coat, and RBCs and successive leukoreduction of RBCs

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood component B
Description: PRBCs obtained by leukoreduction of whole blood, and successive separation of plasma and RBCs

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood component B
Description: PRBCs obtained by leukoreduction of whole blood, and successive separation of plasma and RBCs
Study: NCT03334903

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin
Description: 600 mg gabapentin before and after surgery. 300 mg gabapentin for approx. 5 weeks after surgery.
Study: NCT02091934

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Wavefront-guided PRK
Description: Wavefront-guided PRK

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Wavefront-optimized PRK
Description: Wavefront-optimized PRK
Study: NCT02144012

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trastuzumab
Description: For the first three-week cycle, trastuzumab was administered IV at 8 mg/kg. For subsequent cycles, trastuzumab was administered IV at 6 mg/kg Q3W.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab Emtansine
Description: Trastuzumab emtansine 3.6 milligrams/kilogram (mg/kg) was administered intravenously (IV) over 30-90 minutes Q3W.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Docetaxel was administered IV at either 75 milligrams/square meter (mg/m\^2) or 100 mg/m\^2 Q3W.
Study: NCT01734863

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: External Beam Radiotherapy
Study: NCT02080949

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 4fx x 5Gy
Description: It'll be recruited 3 patients to the initial scheme of 4 fractions of 5 Gy on each brain metastasis with HSRT and if no patient has unacceptable toxicity, more 3 patients for subsequent scheme will be recruited. If 2 patients had unacceptable toxicity, the study ends and it'll be considered the study initiated with toxic regimen. If 1 patient has unacceptable toxicity, it'll be recruited 3 more patients for this scheme and if 1 or more patients had unacceptable toxicity, the scheme will be considered toxic and the study will be closed. If no patient develops unacceptable toxicity, the study will follow to the next cohort of 3 more patients with next dose level. The same criteria of recruitment will be performed till any scheme reach the MTD or up to the scheme of 4 fractions of 9 Gy.
Study: NCT03910374

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Dural closure
Description: Evaluation of the safety and effectiveness of autologous blood-derived products (L-PRF and fibrinogen) compared to the fibrin sealants as an adjunct for dural repair

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Dural closure
Description: Evaluation of the safety and effectiveness of autologous blood-derived products (L-PRF and fibrinogen) compared to the fibrin sealants as an adjunct for dural repair
Study: NCT02612727

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Filtered-sunlight phototherapy
Description: Infants will receive \>= four hours per day of filtered-sunlight phototherapy for 1 to 10 days. The filtering will be done using Air Blue 80 window tinting film.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intensive phototherapy
Description: Infants will receive \>= four hours per day of intensive phototherapy for 1 to 10 days.
Study: NCT00394147

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed
Description: pemetrexed 500mg/m2 given on day 1 and day 15 of each 28 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine
Description: gemcitabine 1500mg/m2 given on day 1 and day 15 of each 28 day cycle
Study: NCT03206528

Intervention type: DEVICE
Intervention: Vital Signs Monitoring System
Description: The VSMS will be adhered to each enrolled patient for the entire hospitalization period.

Intervention type: DEVICE
Intervention: Vital Signs Monitoring System
Description: The VSMS will be adhered to each enrolled patient for the entire hospitalization period.
Study: NCT02481232

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: freeze-dried group ACYW135 MCV
Description: Group A, C, Y and W135 Meningococcal conjugate vaccine is suitable for immune prevention of epidemic cerebrospinal meningitis more than 2 months of age population

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: freeze-dried group ACYW135 MCV
Description: Group A, C, Y and W135 Meningococcal conjugate vaccine is suitable for immune prevention of epidemic cerebrospinal meningitis more than 2 months of age population
Study: NCT02088281

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indigo naturalis extract in oil ointment
Description: Apply 0.5 g of INEO ointment per 10 x 10 cm psoriasis lesion twice daily.
Study: NCT03991572

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: repeated transcranial magnetic stimulation with real coil
Description: repeated transcranial magnetic stimulation with real coil is a noninvasive technique to activate and modify the activity of the neurons

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: repeated transcranial magnetic stimulation with sham coil
Description: repeated transcranial magnetic stimulation with sham coil is a placebo
Study: NCT00176228

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamotrigine
Description: It is a mood stabilizer that is clinically the first choice if patients present with depression and is effective in adults for mania in maintenance phase. So it is administered to see how effective it is in children and adolescents.~The dose of lamotrigine will be 12.5 mg per day beginning the first day. It is increased in 12.5 mg increments every week until it reaches 50 mg and 25 mg per week of increment thereafter until maximum dose of 150 mg in those below 50 kg and 200-400 mg depending on clinical response in those above 50 kg.
Study: NCT03778762

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Blind tracheal intubation through AirQ
Description: underwent blind intubation with correction manoeuvres

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Fiberscopic tracheal intubation through AirQ
Description: : underwent fibreoptic guided intubation
Study: NCT01446289

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Group B Streptococcus Trivalent Vaccine
Description: Pregnant women who received one injection of Group B Streptococcus Trivalent Vaccine administered intramuscularly.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pregnant women who received one injection of saline solution administered intramuscularly.
Study: NCT04534959

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Targeting Normoxemia (SpO2 90-96%; PaO2 60-100 mmHg)
Description: Post-implementation of targeted normoxemia through oxygen titration for individual patients. Interventions for treatment of hypoxemia will follow usual local practice. Interventions for treatment of hyperoxemia (SpO2 \>96% or PaO2 \>100 mmHg) will involve down titration of FiO2 (or supplemental oxygen for non-mechanically ventilated patients) within a time frame based on local site preferences-typically in increments of no greater than 0.10 until goal oxygenation in the normoxemia range is achieved (including room air \[no supplemental oxygen\] for non-mechanically ventilated patients).
Study: NCT01209260

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Radiofrequency energy needle
Description: Radiofrequency energy needle for transseptal access

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Mechanical Needle
Description: Mechanical needle for transseptal access
Study: NCT03310775

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parent-assisted social skills training program for young adult with ASD
Description: The subjects will participate in the treatment program weekly for a total of 16 weeks. The final visit will be made at the point four months after the completion of treatment to see long-term effects.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parent-assisted social skills training program for young adult with ASD
Description: The subjects will participate in the treatment program weekly for a total of 16 weeks. The final visit will be made at the point four months after the completion of treatment to see long-term effects.
Study: NCT05015465

Intervention type: DIAGNOSTIC_TEST
Intervention: Anterior Segment OCT
Description: AS-OCT for juvenile SLE patients and compare them with normal subjects

Intervention type: DIAGNOSTIC_TEST
Intervention: Anterior Segment OCT
Description: AS-OCT for juvenile SLE patients and compare them with normal subjects
Study: NCT03466008

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Whole-Body Cryotherapy
Description: 10 sessions of WBC were performed (in addition to usual care) in a standard cryotherapy room over a duration of 8 days.
Study: NCT01031355

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estradiol Valerate (EV) / Levomefolate Calcium (BAY98-7078)
Description: Oral, single dose, 3 mg EV + 0.451 mg levomefolate calcium, washout phase between treatments: at least 7 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Estradiol Valerate (EV) (BAY86-4980)
Description: Oral, single dose, 3 mg EV, washout phase between treatments: at least 7 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levomefolate Calcium (BAY86-7660)
Description: Oral, single dose, 0.451 mg levomefolate calcium, washout phase between treatments: at least 7 days
Study: NCT03119584

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: linaclotide or placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: linaclotide or placebo
Study: NCT00803725

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mepivacaine without fentanyl
Description: 45 mg 1.5% mepivacaine injection for spinal anesthesia

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mepivacaine with Fentanyl
Description: 10 micrograms fentanyl with 30 mg 1.5% mepivacaine injection for spinal anesthesia
Study: NCT01063452

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Truvalve
Description: Atkinson Product Design urinary slide valve
Study: NCT00641706

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic conventional surgery
Description: Patient undergoes surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Description: Given IV
Study: NCT01063452

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control (catheter drainage bag)
Description: urinary catheter drainage bag
Study: NCT00641706

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Description: Given IV
Study: NCT03570021

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: total thyroidectomy with bilateral prophylactic central compartment (level VI) neck dissection
Description: total thyroidectomy with bilateral prophylactic central compartment (level VI) neck dissection as defined by the American Thyroid Association \[American Thyroid Association Surgery Working Group, Thyroid 2009\]. This is a standard treatment recognized by the French Society of Otolaryngology Head and Neck Surgery \[French Society of Otolaryngology Head and Neck Sugery\].~- The number of lymph nodes resected, the number of metastatic nodes, their size and the presence or absence of extranodal spread will be recorded. Due to the large natural variability of the number of lymph nodes retrieved in a prophylactic neck dissection \[Hartl DM, Ann Surg 2012\], no patient will be excluded on the basis of number of lymph nodes. Furthermore, the participating surgeons routinely perform complete central neck dissections, and were chosen to participate in this study due to a homogenous technique among these surgeons \[Hartl DM, World J Surg 2012\].

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: total thyroidectomy alone without neck dissection
Description: This is recognized as a standard treatment by the Francophone Association of Endocrine Surgery
Study: NCT02435784

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: The Two-Way Communication Checklist
Description: The Two-Way Communication Checklist (2-COM) is a communication tool developed by Van Os et al. (2002). It aims to provide an opportunity for patients to voice their needs and problem to minimize the discrepancy and miscommunication between patient and professional carer. 2-COM questionnaire was designed to give patients while they are waiting for consultation. Patients can either tick yes or no in the questionnaire to decide which the perceived problems are and which needs they want to discuss with the clinician. During the consultation, the ticked items would be discussed.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Treatment as usual
Description: Patients will attend a psychiatric consultation as usual.
Study: NCT03771677

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nucleotide Analog
Description: such as Entecavir,entecavir 0.5mg per day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nucleotide Analog
Description: such as Entecavir,entecavir 0.5mg per day
Study: NCT03230357

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PICC guided by EDUG
Description: ECG Doppler ultrasound guidance technology (EDUG) is the combination of MST puncture and ECG technology through the use of ECG Doppler ultrasound machine and valve conduction PICC to conform the localization of EDUG technology by the study of real-world
Study: NCT00251017

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Vancomycin
Description: Two hour creatinine clearance before and after vancomycin

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: DNA are extracted from the whole blood of subjects
Study: NCT04520308

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dupilumab Only Product
Description: SC injections of 300 mg dupilumab every 2 weeks for 24 weeks following a loading dose of 600 mg on day 1
Study: NCT00087386

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tanespimycin
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT02619058

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NKT cells
Description: autologous natural killer T cell

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NKT cells
Description: autologous natural killer T cell

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NKT cells
Description: autologous natural killer T cell
Study: NCT05475444

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Chitosan Coated PLGA nanoparticles entrapping Ciprofloxacin incorporated in smart gels
Description: antibacterial nanoparticles were used because of their small size, sustained release and positive charge which interact with the negatively charged surface of bacterial cell causing its destruction.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin paste and solution
Description: Conventional antibacterial paste and solution were compared to nanoparticles smart gels to treat endodontics bacterial infection
Study: NCT00479934

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: imatinib mesylate
Description: 6 month treatment with 400mg/day (per os)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: imatinib mesylate
Description: 6 month treatment with 400mg/day (per os)
Study: NCT03147573

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 1-hour blood pressure monitoring (1BPM)
Description: This method consists of performing blood pressure measurements programmed at 5-min intervals over 1 hour. Two extra recordings taken at the start and end of this period are discarded. Blood pressure is measured in a quiet room at the same health centre.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 24-hour ambulatory blood pressure monitoring (ABPM)
Description: The device is programmed to record the participant's BP every 20 min and 30 min during the day and night, respectively. Participants are advised to carry on with their normal daily activities, avoiding any intense physical exertion, and to remain at rest when their BP is being measured.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Office blood pressure measurement (OBPM)
Description: Two readings were made one minute apart with a validated automatic sphygmomanometer in a sitting position after five minutes of rest. The average of two readings is calculated. The procedure is repeated during 3 office visits at least a week apart.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Home blood pressure monitoring (HBPM)
Description: For each blood pressure recording, at least two consecutive measurements should be taken, at least one minute apart. Blood pressure should be recorded twice daily, ideally in the morning and evening. Blood pressure recording should continue for at least four consecutive days, ideally seven. The average of the above readings should be calculated, ignoring the first day.
Study: NCT02373306

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sustained or hemodynamically unstable arrhythmia induction during non-invasive programmed stimulation
Study: NCT00287846

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: imatinib mesylate
Study: NCT02619006

Intervention type: OTHER
Intervention: Delayed Cord Clamping or Cord Milking
Description: Healthy term infants who were previously randomized or assigned at birth to the intervention group known as delayed cord clamping. The cord was clamped and cut at or beyond 300 seconds (5 mins). Cord milking (cord milked x 5) was used as a proxy for delayed cord clamping when there was a clinical situation of concern.
Study: NCT00864344

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sertraline HCl 100 mg tablets, single dose
Description: A: Experimental SSubjects received Purepac formulated products under fasting conditions

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zoloft® 100 mg tablets, single dose
Description: B: Active comparator Subjects received Pfizer formulated products under fasting conditions